"Until these vaccines that are known to cause side effects, including death, are out of their trial stages, one can determine what is a coincidence a healthy person ends up dead after the jab or having a similar but unrelated outcome.
We are after all gathering the data otherwise we would have a better line to draw would we not?"
Well if you are looking for data you cannot go past the following research paper. (Heaps of data in the report and supplementary material):
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study"
Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021.
PARTICIPANTS 29,121,633 people were vaccinated with first doses (19,608,008 with Oxford-AstraZeneca (ChAdOx1 nCoV19) and 9,513,625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1,758,095 people had a positive SARSCoV-2 test. People aged ≥16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study
The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events.
Results
Table 1 shows the characteristics of 19,608,008 people who had the ChAdOx1 nCoV-19 vaccine, 9,513,625 who had the BNT162b2 mRNA vaccine, and 1,758,095 with a SARS-CoV-2 positive test. During the study period, among those vaccinated,
9,764 people had a hospital admission related to thrombocytopenia (52 deaths) and
23,390 people were admitted to hospital with venous thromboembolism (1,871 deaths);
this included 119 people with CVST related hospital admissions (no deaths).
Hospital admission related to arterial thromboembolic events occurred in 89,321 people (6,533 deaths);
these included 28,222 ischaemic strokes (4,204 deaths),
62,699 with myocardial infarction (2,875 deaths), and
3655 with other rare arterial thrombotic events (84 deaths).
Table 2 shows the demographic characteristics of patients who experienced the primary outcomes of interest in the 28 days after exposure.
Supplementary table 2 shows corresponding results for the secondary outcomes.
Table 3 and figure 1 show the number of patients with outcome events in each time period and the incidence rate ratios for outcomes in the risk periods immediately before and after each exposure.
The study found:
- increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days);
- increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and
- increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days)
Secondary analyses found:
- increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), , and after a positive SARS-CoV-2 test
- increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test;
- increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test.
Conclusion Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines.
The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.
PLEASE NOTE: The 1,758,095 people that had a positive SARSCoV-2 test were all vaccinated!! THIS IS NOT A COMPARISON OF THE RISKS OF VACCINATION VS THE RISKS FROM SARSCoV-2 IN THE UNVACCINATED. IE. THEY APPEAR TO BE 1,758,095 BREAKTHROUGH INFECTIONS IN THE VACCINATED AND THEREFORE THE ADVERSE EVENTS REPORTED HERE IN THIS GROUP STILL REPRESENT A RISK FROM VACCINATION. (I only noted this today when I returned to the site to repost here and read the comments section on that site);
Extracts from discussion:
Our analysis of serious adverse events leading to hospital admission or death, covering a population of over 29 million vaccinated people in England, showed increased relative incidences of thrombocytopenia and venous thromboembolism in the 8-14 days after ChAdOx1 nCoV-19 vaccination but not of arterial thromboembolism. Conversely, BNT162b2 mRNA vaccination was associated with arterial thromboembolism 15-21 days after vaccination but not with thrombocytopenia or venous thromboembolism. For our prespecified secondary outcomes, we found an increased risk of CVST and other rare arterial thrombotic events at 8-14 days after the ChAdOx1 nCoV-19 vaccination. We also found an increased risk of CVST and ischaemic stroke at 15-21 days after vaccination with BNT162b2 mRNA. The increased risks for CVST for both vaccines might be a potential signal, although numbers were small and further confirmation is needed. The small absolute risks associated with both of the vaccines should be noted; for instance, for 10 million people exposed to the ChAdOx1 nCoV-19 vaccine, there were seven excess events of CVST in the 28 days after the vaccine.
The subgroup analysis by age group has shown no association between CVST and the BNT162b2 mRNA vaccine, but a strong association with ChAdOx1 nCoV19 in those younger than 50 years old (incidence rate ratio 6.36, 95% confidence interval 2.61 to 15.46). However, the sample size was considerably lower in the subgroup analyses, especially for the BNT162b2 mRNA vaccine (fewer than five people in each risk interval). However, the point estimate of incidence rate ratio associated with the BNT162b2 mRNA vaccine remained large (3.90, 0.96 to 15.82 at 15-21 days), suggesting a signal for CVST after vaccination.
Source: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study | The BMJ
Supplementary Data Table:
Template (bmj.com)
Regards
SP
